Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The latest funding round came hard on the heels of $75 million the company raised in March, giving the company a total of $177 million raised in the first half of 2020.
Through the partnership, Takeda will have access to Twist’s “Library of Libraries,” a large phage display library created using precisely defined synthetic DNA sequences to discover unique antibodies to important therapeutic targets including GPCRs.
What if you could get one vaccine that protects you against a wide spectrum of viruses, even viruses we haven’t discovered yet?
On Tuesday, the White House notified Congress and the United Nations of the decision. However, the withdrawal will not be immediate.
Foghorn Therapeutics entered into a strategic collaboration with Merck to leverage Foghorn’s Gene Traffic Control platform for cancer therapies.
IM Therapeutics is developing a personalized, orally available small molecule therapeutic for diabetes. This is a milestone for autoimmune diseases and may be the first time diabetes patients can be preselected for a therapeutic based on whether they carry a specific gene.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.
GlaxoSmithKline is providing its pandemic adjuvant technology to another company to bolster the chances of developing a vaccine against COVID-19.
Putting your employees and company culture first keeps the focus on inclusion and innovation, giving the company an incredible competitive advantage.
Vor secured $110 million in a Series B financing round that will be used to advance the company’s lead stem cell-based oncology asset into clinical trials.